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Abstract 
Twenty-four quinoxaline derivatives were evaluated for their antimycobacterial 
activity using BacTiter-Glo microbial cell viability assay. Five compounds showed 
MIC values < 3.1 µM and IC50 values < 1.5 µM in primary screening and therefore, 
they were moved on for further evaluation. Compounds 21 and 18 stand out, showing 
MIC values of 1.6 µM and IC50 values of 0.5 and 1.0 µM respectively. Both 
compounds were the most potent against three evaluated drug-resistant strains. 
Moreover, they exhibited intracellular activity in infected macrophages, considering 
log-reduction and cellular viability. In addition, compounds 16 and 21 were potent 
against non-replicating M. Tb. and compound 21 was bactericidal. Therefore, 
quinoxaline derivatives could be considered for making further advances in the future 
development of antimycobacterial agents. 
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Tuberculosis (TB) is a chronic infection caused by Mycobacterium tuberculosis (M. 
Tb.), which is the second cause of death from a single infectious agent. Due to its high 
infectivity it is estimated that a third of the world population is a reservoir of 
Mycobacterium.  
In 2000, within the Millennium Development Goals (MDG6), the United Nations 
proposed to halt the spread and reverse the incidence of TB by 2015. Some of these 
objectives have already been achieved. The TB mortality rate has decreased 45% since 
1990 and more people have access to effective treatments and to early and sensitive 
diagnostic methods. However, epidemiological data are still alarming
1
. According to 
World Health Organization (WHO) data, 9 million people were infected by 
tuberculosis bacillus in 2013, including 1.1 million cases among people living with 
HIV. In 2013, 1.5 million people died due to tuberculosis infection, with this being the 
main cause of death among people affected by HIV. In addition, the number of 
infected people with multidrug-resistant TB (MDR-TB) is increasing annually. The 
ability of M. Tb. to develop resistance to drugs and the difficulties faced in the 
treatment of the TB-disease has facilitated the development of resistant strains. MDR-
TB has been spreading rapidly in the last decades, especially in recent years; the 
number of individuals infected with MDR-TB tripled between 2009 and 2013, and 
reached 136,000 worldwide
2
.  
These data indicate the urgent need to continue working in the development of new 
compounds against new targets and with new mechanisms of action for treating MDR-
TB. It is also important to shorten the long periods of treatment because they are a 
common reason for treatment discontinuation on the part of the patient, and stopping 
the treatment too early is related with the appearance of resistant strains
3
. With this 
aim, our group has been working for several years on the synthesis and biological 
evaluation of new structures derived from quinoxalines. Quinoxaline derivatives show 
very interesting biological properties. Several studies have been published which 
justify the interest in these derivatives as antibacterial agents. As a result of our anti-
tuberculosis research project, several papers have been published in which both 
synthesis and biological activity assessments have been described for a large number 
of quinoxaline and quinoxaline 1,4-di-N-oxide derivatives with a variety of 
substituents. Some of them have shown growth inhibition values of 99% and 100%
4-9
. 
This indicates that these types of structures are very interesting for developing new 
anti-TB molecules. Furthermore, it has been reported that oxidation of the nitrogen in 
the quinoxaline ring provides a significant increase in the antibacterial biological 
activity.
10
 It has also been reported that the quinoxaline 1,4-di-N-oxide derivatives 
suffer a bioreduction process under hypoxic conditions
11
. This behavior could be 
interesting because in the caseous core of the tuberculous granulomas there is a low 
concentration of oxygen where non-replicating persistence (NRP) forms of M. Tb. 
bacilli can survive
12
. These forms are thought to be the reason behind the need for long 
treatments and the development of tolerance to the treatment
13
.  
Chalcones are precursors of flavonoids and isoflavonoids, which consist in two 
aromatic rings linked by a 3 carbons chain presenting an α,β-unsaturated ketone 
system. Chalcones exhibit a wide range of biological activities such as anticancer, 
anti-leishmaniasis, anti-inflammatory, anti-oxidant and anti-tuberculosis. With regard 
to the anti-mycobacterial activity of chalcones, there are numerous publications that 
justify their use in the search for new anti-TB compounds
14, 15
.  
Fluoroquinolones are an important group of broad spectrum antibiotics and they are 
present in many molecules with high antituberculosis activity such as gatifloxacin and 
moxifloxacin, which are under development in clinical trials
16
.  
With the aim of developing new antitubercular drug candidates, we have synthesized 
and evaluated 24 quinoxaline derivatives. The design was based on the molecular 
hybridization of the quinoxaline 1,4-di-N-oxide with chalcone and fluoroquinolones 
scaffolds
17
. (Figure 1) 
We report the design and synthesis of the quinoxaline 1,4-di-N-oxide derivatives 1-24. 
The biological evaluation of the compounds included a M. Tb. H37Rv dose-response 
assay (primary screening) in which the IC50, IC90 and MIC against M. Tb. were 
determined. The most active compounds were moved on to a more advanced testing 
stage for antimycobacterial activity. These assays included the evaluation against 
single drug-resistant (SDR) strains of M. Tb., Minimum bactericidal concentration 
(MBC), Low Oxygen Recovery Assay (LORA) and intracellular drug activity. All 
results are reported and structure-activity relationships (SARs) are discussed. 
The quinoxaline 1,4-di-N-oxide derivatives were synthesized through the synthetic 
process illustrated in Scheme 1. 
 
 Scheme 1: General synthesis of quinoxaline 1,4-di-N-oxide derivatives.  
Reagents and conditions: (i) N,N-DMF, NaOCl, low temperature; (ii) ethanolamine, CaCl2; (iii) microwave assisted 
synthesis; (iv) NaOH, MeOH, ice bath; (v) NaOH, MeOH, freezing bath; (vi) N,N-DMF, reflux; (vii) CH3CN, 
Et3N, rt.; (viii) CH3CN, DBU, 50ºC. 
The starting benzofuroxans, were commercially available or were obtained by 
previously described methods
18
. The synthesis of quinoxaline 1,4-di-N-oxide 
intermediates were carried out by a variation of the Beirut reaction following the 
procedure described in the literature
19-21
. 
The 10 novel chalcone analogs (1-10) were prepared by Claisen-Schmidt 
condensation
22
. Benzaldehyde, 5-nitro-2-furaldehyde and 5-nitro-2-
thiophenecarboxylaldehyde were used as the starting aldehyde. The corresponding 
quinoxaline 1,4-di-N-oxide previously synthesized was used as the ketone. The new 
derivatives 1-10 were unsubstituted or substituted in R
1
 or R
2
 positions by methyl 
moiety as electron-releasing groups and by chlorine moiety as electron-withdrawing 
groups.  
The methodologies for the synthesis of compounds 11-15, 17-20 and 22-24 were 
previously described by our group
19
. Compound 16 and 21 were obtained by 
nucleophilic aromatic substitution of chlorine or fluorine linked to R
1
/R
2
 substituent 
on the quinoxaline ring. Morpholine and 1-(4-fluorophenyl)piperazine were used as 
the nucleophilic amine. Compound 16 was obtained by reflux using N,N-DMF and 
compound 21 was obtained using DBU as base.  
The identification of novel interesting compounds begins with a primary screening. 
This initial dose response assay evaluates the ability of compounds to inhibit the M. 
Tb. replication. The IC90, IC50 and MIC of the 24 quinoxaline 1,4-di-N-oxide 
derivatives were determined against M. Tb. H37Rv (ATCC 27294) using BacTiter-Glo 
(BTG) microbial cell viability assay.  
The structure and anti-tuberculosis activity data of the 24 compounds are shown in 
Table 1. Nine out of twenty-four evaluated compounds exhibited MIC values ≤ 6.2 
µM and IC50 values < 3.7 µM. Compounds 3, 16, 18, 21 and 24 were the most active, 
showing MIC values among 1.6-3.1 µM and IC50 values among 0.5-1.5 µM. These 
MIC and IC50 values were lower than those of the second-line reference drugs 
cycloserine and pyrimethamine, and also by the first-line drug ethambutol. It is worth 
noting that 4 out of the 5 most active compounds (16, 18, 21 and 24) are 
fluoroquinolone analogs while compound 3 belongs to chalcone analogs.  
Table 1. Biological results against M. Tb. H37Rv dose-response assay 
Code  
Activity against M. Tb. 
under aerobic  
conditions Code  
Activity against M. Tb. 
under aerobic 
conditions 
R4 R3 R2 R1 
IC50 
(µM) 
IC90  
(µM) 
MIC 
(µM) 
R4 R3 R2 R1 
IC50 
(µM) 
IC90 
(µM) 
MIC 
(µM) 
1 CH3  H H 5.8 11.5 12.5 16 CF3  Cl  1.2 2.1 3.1 
2 CH3  H CH3 7.2 14.7 25.0 17 CF3 CH3 F  5.4 10.7 12.5 
3 CH3 
 
H Cl 1.5 1.7 3.1 18 CF3 CH3 F  1.0 1.5 1.6 
4 CH3  H H 17.3 24.6 25.0 19 CF3 CH3   2.2 4.6 6.2 
5 CH3  H CH3 29.7 38.1 50.0 20 CF3 CH3 F 
 
4.0 7.2 12.5 
6 CH3  H Cl 13.5 20.8 25.0 21 CF3 O-CH3 H 
 
0.5 0.8 1.6 
7 CH3  H H >100 >100 - 22
a CF3 OCH2CH3 Cl  >100 >100 - 
8 CH3  H CH3 >100 >100 - 23 CF3 CH(CH3)2   8.3 17.9 25.0 
9 CH3  H Cl 7.3 13.0 25.0 24 CF3 CH3 F  1.3 1.8 3.1 
10 CH3  Cl Cl >100 >100 - Amikacin 0.1 0.1 0.2 
11 CF3  H Cl 3.7 4.5 6.2 Cycloserine 20.8 33.1 50.0 
12 CF3  Cl Cl 3.6 4.5 6.2 Ethambutol 1.2 1.8 6.2 
13 CF3 
 
H F 3.1 4.0 6.2 Isoniazid 0.1 0.2 0.3 
14 CF3 
 
F F 5.2 8.0 12.5 Pyrimethamine 23.6 36.0 50.0 
15
 a
 CF3  Cl  >100 >100 - Rifampicin 0.02 0.03 0.04 
a: quinoxaline-1-N-oxide  
In comparison with fluoroquinolones, the presence of an electron-withdrawing 
substituent (fluorine or chlorine) in only one of the R
1
 and R
2
 positions in the 
quinoxaline ring is important for biological activity. This behavior is observed 
comparing the biological results obtained for compound 3 vs 1 and 2, 6 vs 5, 9 vs 7, 8 
and 10, 13 vs 14, 18 vs 19 and 24 vs 23.  
With respect to R
4
 substitutions, 8 out of 9 most active compounds present a 
trifluoromethyl group. The substitution of hydrogen by its bioisostere fluorine is a 
widely used strategy in the search for new compounds. The presence of fluorine atoms 
can change and radically modulate the physicochemical properties of organic 
compounds modifying its biological behavior 
23
. However, it is not possible to carry 
out a SAR study due to the limited structural variability in this position. 
With regard to R
3
 position, it seems to be less important for the anti-mycobacterial 
activity. 
With regard to N-oxide groups of the quinoxaline ring, these groups seem to be 
essential for the activity as we can see comparing compounds 15 vs 16. This important 
loss of activity confirmed again that the presence of the both N-oxide groups is a 
structural requirement for biological activity 
24, 25
.  
According to obtained results, compounds 3, 16, 18, 21 and 24 (MIC < 6.25 µM) were 
submitted for advanced anti-mycobacterial susceptibility profiling. This advanced 
screening includes the determination of MIC against SDR strains of M. Tb., MBC, 
LORA as well as intracellular drug screening study in infected macrophages and a 
MTT cell proliferation study in uninfected macrophages at different concentrations. 
Table 2 shows the MIC values of the selected compounds against rifampin (RIF), 
isoniazid (INH) and ofloxacin (OFX) resistant strains and a retested MIC value against 
a susceptible strain.  
Table 2. Minimum inhibitory concentration against single-drug resistant strains of M. Tb. 
Code Structure 
H37Rv 
INH-R 
M. Tb. 
RIF-R  
M. Tb. 
OFX-R  
M. Tb. 
SRI 1345 strain SRI 1369 strain SRI 1367 strain SRI 4000 strain 
MIC 
µg/mL 
% 
Inh(a) 
MIC 
µg/mL 
% 
Inh. 
R(b) 
MIC 
µg/mL 
% 
Inh. 
R(b) 
MIC 
µg/mL 
% 
Inh. 
R(b) 
3 
 
2 80 1 64 2 0.5 51 4 0.5 100 4 
16 
 
2 61 0.5 78 4 0.5 66 4 0.25  76 8 
18 
 
1 78 0.25  57 8 0.25 68 8 0.25  84 8 
21 
 
1.5 78 0.19  51 8 0.19 73 8 0.19  81 8 
24 
 
0.75 51 0.75 89 1 0.38 75 2 0.19  62 4 
RIF  0.05 55 0.05 72     0.195 53  
INH       0.02  55     
a: Percentage inhibition at the MIC concentration.  
R: Ratio of MIC H37Rv/MIC Resistant-strain 
INR-R: isoniazid-resistant 
RIF-R : rifampin-resistant 
OFX-R: ofloxacin-resistant 
In general, the OFX-resistant M. Tb. strain was the most sensitive to the 5 tested 
compounds. The susceptibilities of INH, RIF and OFX-resistant strains can be 
considered greater than those of H37Rv, as indicated by the ratios of MICs against non-
resistant and resistant strains which are between 2 and 8. Only compound 24 showed 
low resistance with INH-resistant strain with a ratio = 1. 
These results suggest that all compounds were active against RIF, INH and OFX-
resistant M. Tb. strains. Therefore, there is no cross-resistance with the antitubercular 
drugs used in the assay, supporting the idea that our compounds act through a different 
mechanism of action. These results are promising for the development of new 
effective compounds against the growing number of drug-resistant strains.  
A compound is considered as bactericidal if the ratio MBC/MIC is ≤ 426. This is 
important because bactericidal drugs can potentially shorten the standard treatment 
regimen, which is a minimum of 6 months for tuberculosis. Therefore and according 
to the results showed in Table 3, compound 21 could be considered as bactericidal due 
to the low ratio obtained. If a compound lacks bactericidal activity, many times the 
colony-forming units (CFUs) are too numerous to count (TNTC) as observed with 
compound 16 
27
.  
Table 3. Minimum bactericidal concentration and Low Oxygen Recovery Assay results.  
Code 
MIC H37Rv MBC LORA 
µg/mL % Inh
a
 µg/mL 
MBC/ 
MICH37Rv 
µg/mL 
MIC H37Rv 
/LORA 
3 2 80 NA - UR - 
16 2 61 TNTC - 0.25 8 
18 1 78 NA - >8 Nd 
21 1.5 78 4 2.6 0.375 4 
24 0.75 51 NA - >12 Nd 
RIF 0.05 55 0.78 15.6 0.39 - 
a: Percentage inhibition at the MIC concentration. UR: Unreportable: Compound precipitated out of solution.  
NA: Not applicable: colony counts above the established rejection value ≥ 40. TNTC: Too numerous to count. 
Nd: Not determinated.  
It is well known that quinoxaline 1,4-di-N-oxide possess a selective toxicity against 
hypoxic tumoral cells through a bioreductive activation process
28
. In the case of 
tuberculosis, the granulomatous lesions formed in the infected lungs present a hypoxic 
environment where TB bacilli are in a latent state of low metabolic activity. These 
nonreplicating persistence (NRP) M. Tb. bacilli is thought to be a main factor 
responsible for the long treatment periods and the emergence of antimicrobial 
tolerance
29
. Therefore, special attention should be paid to the NRP state of M. Tb. from 
the early stages of the drug discovery process.  Therefore, the LORA assay, conducted 
under low oxygen conditions, has been included in the biological evaluation with the 
aim of identifying compounds able to acting on the non-replicative bacilli. As shown 
in Table 3, compounds 16 and 21 were more potent against NPR M. Tb. being 8-fold 
and 4-fold more active under anaerobic conditions than aerobic conditions 
respectively. These results offer an important approach for studying this family of 
compounds in these conditions due to the important role that NRP M. Tb. bacilli play 
in influencing the duration of treatment. 
M. Tb. can evade the immune response of macrophages and has the ability to reside 
inside them in a latent state. This evasion mechanism makes the effectiveness of 
treatment difficult and increases the microbial resistance
30, 31
.  
With the aim of assessing the intracellular effectiveness of the 5 selected compounds 
in this infection phase, the activity in J774 infected macrophages was evaluated. 
Compounds 3, 16, 18, 21 and 24 were tested at three 10-fold concentrations based on 
their MIC values against M. Tb. H37Rv. 
All of the evaluated compounds showed high log-reduction in the burden of the 
intracellular bacilli (Table 4). However, it was observed that none of the evaluated 
compounds showed dose response log-reduction in contrast to RIF.  
At the lowest concentration, compounds 3 and 24 showed values > 2-log-reduction (> 
99% inhibition) while compounds 16, 18 and 21 showed values > 1-log-reduction (> 
90% inhibition). Therefore, the 5 evaluated compounds exhibited log-reduction among 
3 to 4.5-fold more than RIF. 
Compounds 16, 18 and 21 showed the highest log-reduction at the highest 
concentration and presented values of 26%, 65% and 47% of cellular viability 
respectively at this concentration. Therefore, compounds 18 and 21 stand out as being 
the most potent derivatives against intracellular bacilli, considering log-reduction and 
cell viability values.  
Table 4. Intracellular activity in M. tb infected J774 macrophages. 
Code 
Log reductiona % of cellular viability 
Low 
concb 
Mid 
concb 
High 
concb 
Low 
concb 
Mid 
concb 
High 
concb 
3 2.11 1.68 1.76 70 81 26 
16 1.68 1.57 2.67 88 37 37 
18 1.74 1.5 2.66 83 53 65 
21 1.43 1.41 3.86 60 64 47 
24 2.17 1.66 1.76 70 81 26 
RIF 0.48 1.73 2.68 93 87 80 
a Intracellular drug activity is reported as log reduction values calculated as reduction in Mtb concentration from zero hour to 7 
days post-infection. 
b The three concentrations chosen were based on the MIC data generated in the HTS primary screen. The mid concentration 
bracketed the reported MIC with the lower concentration ten-fold below the mid and the higher concentration ten-fold above the 
mid. 
 
In conclusion, we describe the synthesis of 12 new compounds and the 
antimycobacterial evaluation of 24 quinoxaline di-N-oxide derivatives. Five of the 
tested compounds passed the first cut-off established in the primary screening against 
H37Rv, thereby justifying the great interest in this family of compounds. The results 
obtained in the advanced screening (MIC against H37Rv and SDR-strains, MBC, 
LORA, intracellular activity and MTT cell proliferation) confirm the promising 
pharmacological profile of these derivatives. 
Compounds 3, 16, 18, 21 and 24 were active against INH, RIF and OXF-resistant 
strains suggesting that they could act through a different mechanism of action that the 
reference drugs. Moreover, the MIC and LORA assay show that compound 21 is 
potent not only against replicating M. Tb but also against NRP M. Tb. In addition, 
compound 21 could be classified as bactericidal according to the MBC and has also 
stand out in the intracellular drug activity assay. The mechanism of action of these 
compounds has not yet been studied. 
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